JPMorgan Chase & Co. raised its position in Seres Therapeutics Inc. (NASDAQ:MCRB) by 4.8% during the second quarter, Holdings Channel reports. The fund owned 212,617 shares of the company’s stock after buying an additional 9,767 shares during the period. JPMorgan Chase & Co. owned about 0.54% of Seres Therapeutics worth $6,176,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Oxford Asset Management acquired a new position in Seres Therapeutics during the second quarter worth $1,016,000. GSA Capital Partners LLP acquired a new position in Seres Therapeutics during the second quarter worth $273,000. DekaBank Deutsche Girozentrale boosted its position in Seres Therapeutics by 20.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 20,300 shares of the company’s stock worth $606,000 after buying an additional 3,500 shares during the last quarter. Jennison Associates LLC boosted its position in Seres Therapeutics by 67.1% in the second quarter. Jennison Associates LLC now owns 670,639 shares of the company’s stock worth $19,482,000 after buying an additional 269,382 shares during the last quarter. Finally, Swiss National Bank boosted its position in Seres Therapeutics by 76.9% in the second quarter. Swiss National Bank now owns 23,700 shares of the company’s stock worth $688,000 after buying an additional 10,300 shares during the last quarter. 78.28% of the stock is owned by institutional investors.
Seres Therapeutics Inc. (NASDAQ:MCRB) traded down 2.45% during midday trading on Tuesday, reaching $11.53. The company’s stock had a trading volume of 45,960 shares. The company’s 50-day moving average is $11.81 and its 200 day moving average is $22.99. The firm’s market capitalization is $464.36 million. Seres Therapeutics Inc. has a 52 week low of $8.05 and a 52 week high of $44.51.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by $0.24. The company earned $3 million during the quarter, compared to analysts’ expectations of $4.20 million. During the same quarter in the prior year, the company posted ($1.45) earnings per share. The firm’s revenue was up NaN% on a year-over-year basis. Analysts expect that Seres Therapeutics Inc. will post ($2.33) earnings per share for the current fiscal year.
A number of equities analysts recently weighed in on the company. FBR & Co reduced their price target on Seres Therapeutics from $43.00 to $23.00 and set an “outperform” rating for the company in a report on Friday, August 12th. Leerink Swann reiterated a “buy” rating and set a $12.00 price objective on shares of Seres Therapeutics in a research note on Thursday, August 11th. Canaccord Genuity reiterated a “buy” rating and set a $20.00 price objective on shares of Seres Therapeutics in a research note on Monday, August 1st. Bank of America Corp. lowered Seres Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 1st. Finally, Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, July 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $31.57.
In related news, insider Michele Trucksis sold 4,156 shares of the firm’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $35.18, for a total transaction of $146,208.08. Following the transaction, the insider now owns 4,156 shares of the company’s stock, valued at $146,208.08. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John G. Aunins sold 9,390 shares of the firm’s stock in a transaction dated Monday, August 29th. The stock was sold at an average price of $10.87, for a total value of $102,069.30. Following the transaction, the insider now directly owns 192,125 shares in the company, valued at approximately $2,088,398.75. The disclosure for this sale can be found here. Corporate insiders own 41.90% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics Inc. (NASDAQ:MCRB).
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.